Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If they get fast track approval the stock could rocket past $1.
Your comments were perfectly timed.
Wouldn’t it be great if they reach a huge settlement with one or more big players and pay shareholders a special dividend? We can dream.
I sure hope not. The waiting in silence is excruciating but what other option do we have besides selling and moving on? After 10 years I refuse to dump it now.
Another day in the dark for HDVY shareholders.
It was doubly painful to not only see NEO screw HDVY shareholders out of their rightful compensation but at the same time watch NEO stock go up 100-fold while HDVY sank to near bankruptcy.
I’ve never understood Albitar’s motivations. Either way it might be another chance to share in the success of his research.
Most longs have shares? How can a long not have shares? Isn’t the definition of being long mean you hold shares?
Even if that were true, which it’s not, who cares what they were doing 7 years ago. The stock is still 0.0001 with no assets and no future.
It’s a very extensive presentation with charts and graphics that you’d typically see at an industry or investors conference. I haven’t gone through it yet in detail so I don’t know if there is any new info but it does a good job of showing everything in the pipeline and makes a good case for the potential of this company. It’s a bit strange for a filing. I don’t think I’ve ever seen this type of presentation submitted as a filing.
It’s up in the 1.30’s
I haven’t seen any challenge to intel since the resolution of the patent dispute. It doesn’t mean that there hasn’t been any discussion behind the scenes but we’re pretty much in the dark. I’d still be surprised if intel was pursuing a patent for some technology they had no use for.
I’m not sure if it’s time to be bullish or bearish. Is the new leadership better for the company? I guess it can’t get too much worse than the current stock price. Why hasn’t the company generated any buzz on the recent patent award? I haven’t seen any new analysts pick up coverage and the 1 analyst following it hasn’t updated their target price in a long time.
This year has been disappointing thus far.
Does that assume that Intel isn't interested or doesn't need the HDVY patent for it's products?
New patent assigned to PLX a few weeks ago
Patent number: 10280414
Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.
Type: Grant
Filed: June 29, 2017
Date of Patent: May 7, 2019
Assignee: Protalix Ltd.
Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay, Tali Kizhner, Yoseph Shaaltiel
Perhaps this is weighing on the stock. It states the reason as personal so hopefully this has nothing to do with his opinion on the future of the company.
Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director
Moshe Manor to continue to serve in the role until June 30, 2019
May 21, 2019 07:00 ET | Source: Protalix BioTherapeutics, Inc.
CARMIEL, Israel, May 21, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that Dror Bashan has been appointed to serve as the Company’s new President and Chief Executive Officer, and a director, effective June 30, 2019, replacing Moshe Manor, who is stepping down from those roles for personal reasons. Mr. Manor will assist with the transition and continue to work with the Company on a consultant basis.
“Dror brings valuable experience and knowledge in the pharmaceutical industry to our Company, and I am happy to welcome him to Protalix,” said Shlomo Yanai, Chairman of Protalix’s Board of Directors. “Moshe has made a great contribution to our organization over the last four years, and has played a critical role in our development and success in advancing our pipeline. On behalf of Protalix and the Board of Directors, I would like to thank Moshe for his significant contributions and outstanding leadership and wish him great success in his future endeavors.”
“I have the deepest gratitude to Protalix’s employees and its Board of Directors. I have decided that, for personal reasons unrelated to the Company, the time has come to hand over leadership to a new chief executive officer,” said Mr. Manor. “I am very honored to have led this great organization and will continue to watch with excitement and anticipation as Protalix progresses in the development and commercialization of its promising pipeline.”
“I am very proud to become Protalix’s President and Chief Executive Officer, and am looking forward to working with such a talented management team to continue the progress of Protalix’s future development,” said Mr. Bashan. “I believe that my broad experience in the pharmaceutical industry, which covers a range of disciplines in the field, will be a valuable resource for the company. I am very excited about the potential path forward and glad to be part of Protalix’s future.”
Mr. Bashan has over 20 years of experience in the pharmaceutical industry with roles ranging from business development, marketing, sales and finance providing him with both cross regional and cross discipline experience and a deep knowledge of the global pharmaceutical and health industries. From 1998 through 2018, he served in a number of senior positions at Teva Pharmaceutical Industries Ltd. Most recently, he served as Teva’s Senior Vice President, Global Business Development, and was involved in strategic alliances, cross-company strategic projects and the acquisition and divestiture of assets. Mr. Bashan holds a BA in Economics and Business Management from the Tel Aviv University in Tel Aviv, Israel, and an MBA from the Tel-Aviv University.
Maybe Sabby is finally done with their games and will let this go higher?
RMTD doesn’t own any patents so I’m not sure what patents you mean. Can you list the patent numbers?
What patents?
believe what?
Thanks pennypop. Do you know if NEO paid any punitive damages for breaching the contract, or only paid royalties that they owed under the agreement with HDVY? If no meaningful penalties I’m wondering why most companies don’t take the same route as NEO. Worst case they pay the royalties much later down the road. Best case they wait it out and hope the company goes under before any payments are made.
I think the window of opportunity for maximizing revenue potential of the patents closed years ago. The company tried to monetize patents in a variety of ways, most of them were wildly unsuccessful — SVM capital and the iPhone melanoma app come to mind. Attempted partnerships all failed. Either the partners withdrew or in the case of NEO breached the contract.
At this stage it would seem the only viable option is to sell certain patents or the entire company. Other paths would take years and huge amounts of money that HDVY doesn’t have.
Hopefully something happens to turn this stock around. It’s trading as if it has nothing in the pipeline.
Hold on tight. Any day now?
If so I hope that’s not the purchase price. I’m guessing it would amount to less than 30 cents per share.
I guess anything is possible. They could clear this up with a shareholder letter or conference call. We can only hope they will do what’s fair for shareholders although that’s relatively rare in the business world. Even without filings it’s still a public company so they have a fiduciary responsibility to take care of shareholders.
That’s what it seems like should have happened on Jan 1. The notes came due and the company should have paid the $300k plus interest, or the holders had the right to convert the notes into common shares. I’m not sure what would happen if the company didn’t have the money or didn’t have enough shares to pay the note holders. Without filings we’re in the dark.
I’m sure this uncertainty scares away many potential investors. The company needs to get out from under this cloud.
Maybe it’s finally losing the stock symbol and won’t trade much longer?
According to the filing the notes should have been paid on Jan 1 either in cash or common stock. Is that right? If yes the holders no longer have the notes. If they do still hold the notes the company can pay them from the $6 million settlement with NEO.
Looks like it may have formed a bottom here. Inching back up now.
I think the silence is intentional, for better or worse. They are keeping everyone in the dark, probably until they have an agreement in place with 1 or more infringers. It sucks for shareholders who want more info but not much we can do except wait it out. Hopefully the wait isn’t too much longer. It feels like holding a lottery ticket and waiting to see if the number is lucky.
That’s interesting coming from the person proclaiming this would be over $4 in a week.
That explains the recent surge in stock price. It’s usually a good sign when institutional holdings increase and they can provide some stability against the day trading.
Yes and the spread is huge. Just not many shares for sale I guess so buyers and sellers at a stalemate.
Wouldn’t the patent lawyers they had back then have advised them to send an interference letter? Or perhaps they did but HDVY didn’t want or have the money to pay into escrow?
If we shareholders lose yet again after finally winning the patent dispute it will be the ultimate kick in the face.
Good news or bad news for HDVY?
My how far we’ve fallen from the days of going to $4 by end of the week.
That’s good advice. And you’re right, what else can we do but sit and wait?
I think on average it's difficult for people in most countries outside the US to pay those levels of pricing. The US is unique in that the prices aren't regulated and most pharmaceuticals are covered by some type of insurance.
I missed the below story when it was issued a couple months ago. At least this analyst is sticking with his $3 price target quarter after quarter even while the stock price seems stuck in the 40 cent range.
https://www.markets.co/h-c-wainwright-reiterates-their-buy-rating-on-protalix-biotherapeutics-plx/
5 zero's is so demoralizing for a stock. Many systems can't even display a price that low. They should just display a roll of toilet paper.
I wonder if that would be the same after-tax amount that HDVY will book, rather than the $6 million.